ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: The BCR-ABL inhibitor Imatinib and subsequent TKIs, Dasatinib and Nilotinib have dramatically improved survival rates for CML, with some patients even discontinuing treatment due to prolonged molecular remission status55,56.